BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 25849664)

  • 1. Serum metalloproteinase-9 is related to COPD severity and symptoms - cross-sectional data from a population based cohort-study.
    Linder R; Rönmark E; Pourazar J; Behndig A; Blomberg A; Lindberg A
    Respir Res; 2015 Feb; 16(1):28. PubMed ID: 25849664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease.
    Wang H; Yang T; Li D; Wu Y; Zhang X; Pang C; Zhang J; Ying B; Wang T; Wen F
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2369-2376. PubMed ID: 27713627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteolytic biomarkers are related to prognosis in COPD- report from a population-based cohort.
    Linder R; Rönmark E; Pourazar J; Behndig AF; Blomberg A; Lindberg A
    Respir Res; 2018 Apr; 19(1):64. PubMed ID: 29650051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
    Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
    Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between plasma matrix metalloproteinase levels, pulmonary function, bronchodilator response, and emphysema severity.
    Koo HK; Hong Y; Lim MN; Yim JJ; Kim WJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1129-37. PubMed ID: 27313452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease.
    Bolton CE; Stone MD; Edwards PH; Duckers JM; Evans WD; Shale DJ
    Chron Respir Dis; 2009; 6(2):81-7. PubMed ID: 19411568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of shuxuening injection on the levels of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in acute exacerbated chronic obstructive pulmonary disease patients].
    Wang TJ; Xie ZH; Zhao ZZ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Feb; 32(2):191-4. PubMed ID: 22574591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Periodontal health and serum, saliva matrix metalloproteinases in patients with mild chronic obstructive pulmonary disease.
    Yıldırım E; Kormi I; Başoğlu ÖK; Gürgün A; Kaval B; Sorsa T; Buduneli N
    J Periodontal Res; 2013 Jun; 48(3):269-75. PubMed ID: 22967248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Concentrations of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in serum of patients with chronic obstructive pulmonary disease].
    Piesiak P; Brzecka A; Kosacka M; Passowicz-Muszyńska E; Dyła T; Jankowska R
    Pol Merkur Lekarski; 2011 Nov; 31(185):270-3. PubMed ID: 22299526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in induced sputum in patients with asthma and chronic obstructive pulmonary disease and their relationship to airway inflammation and airflow limitation].
    Xin XF; Zhao M; Li ZL; Song Y; Shi Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Mar; 30(3):192-6. PubMed ID: 17572998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory mediators in exhaled breath condensate and peripheral blood of healthy donors and stable COPD patients.
    Hao W; Li M; Zhang C; Zhang Y; Wang P
    Immunopharmacol Immunotoxicol; 2019 Apr; 41(2):224-230. PubMed ID: 31046512
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationship Between Circulating Serpina3g, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinase-1 and -2 with Chronic Obstructive Pulmonary Disease Severity.
    Uysal P; Uzun H
    Biomolecules; 2019 Feb; 9(2):. PubMed ID: 30781876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced exhalation of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with COPD exacerbation: a prospective study.
    Kwiatkowska S; Noweta K; Zieba M; Nowak D; Bialasiewicz P
    Respiration; 2012; 84(3):231-41. PubMed ID: 22832426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of matrix metalloproteinase-9, tissue inhibitors of metalloproteinase-1 and their ratio are associated with impaired lung function in the elderly: a population-based study.
    Olafsdóttir IS; Janson C; Lind L; Hulthe J; Gunnbjörnsdóttir M; Sundström J
    Respirology; 2010 Apr; 15(3):530-5. PubMed ID: 20337997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of correlation between pulmonary function and expression levels of matrix metalloproteinases-9 and tissue inhibitor of metalloproteinase-1 among toluene diisocyanate exposed workers].
    Miao PP; Meng T; Jia Q; Niu Y; Ye M; Ji YQ; Ju R; Chen XL; Shao H; Zheng YX; Dai YF
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 May; 50(5):418-22. PubMed ID: 27141897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression.
    Brajer B; Batura-Gabryel H; Nowicka A; Kuznar-Kaminska B; Szczepanik A
    J Physiol Pharmacol; 2008 Dec; 59 Suppl 6():145-52. PubMed ID: 19218638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma.
    Culpitt SV; Rogers DF; Traves SL; Barnes PJ; Donnelly LE
    Respir Med; 2005 Jun; 99(6):703-10. PubMed ID: 15878486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients.
    Higashimoto Y; Yamagata Y; Iwata T; Okada M; Ishiguchi T; Sato H; Masuda M; Itoh H
    Eur Respir J; 2005 May; 25(5):885-90. PubMed ID: 15863647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity.
    Dimic-Janjic S; Hoda MA; Milenkovic B; Kotur-Stevuljevic J; Stjepanovic M; Gompelmann D; Jankovic J; Miljkovic M; Milin-Lazovic J; Djurdjevic N; Maric D; Milivojevic I; Popevic S
    Eur J Med Res; 2023 Mar; 28(1):127. PubMed ID: 36935521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio in smokers with airway hyperresponsiveness and accelerated lung function decline.
    Lo CY; Huang HY; He JR; Huang TT; Heh CC; Sheng TF; Chung KF; Kuo HP; Wang CH
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1135-1144. PubMed ID: 29692608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.